TG Therapeutics Third Quarter Conference Call - TG THERAPEUTICS INC

Financial Performance:

• Total global revenue reached $260 million in Q3 2026, representing a 61% year-over-year increase.
• U.S. net product revenue (pre-MV) was $233 million, up 52% YoY, with an additional $7.4 million from international partner sales.
• U.S. pre-MV gross margin remained strong at 87%; consolidated gross margin was approximately 84%.
• Total net product revenue was $240 million; license, milestone, and royalty revenue totaled $19.9 million.
• Operating income was $86 million, up significantly from $29 million in Q3 2025.
• Net income was $55.5 million ($0.35 diluted per share), noting that Q3 2025 included a substantial non-cash tax benefit.
• R&D and SG&A expenses (excluding stock-based compensation) totaled $107 million, down from $150 million in Q2 2026.
• The company generated significant cash flow, ending September with $557 million in cash, cash equivalents, and investments.
• Capital allocation included $100 million in stock repurchases during the quarter (approx. 2 million shares) and $300 million cumulative repurchases to date.

Guidance and Future Outlook:

• Full-year 2026 global revenue guidance raised to approximately $1 billion.
• U.S. pre-MV net product revenue guidance raised to $915–$920 million (previously $890–$905 million).
• Q4 2026 projected U.S. revenue to exceed $260 million, pushing the U.S. franchise above a $1 billion annualized run rate.
• Full-year 2026 R&D and SG&A expenses (excluding stock-based comp) expected to remain in the $450–$500 million range.
• Simplified IV initiation regimen (Enhanced) targeting potential regulatory approval and label update around mid-2027.
• Subcutaneous BrionV Phase 3 top-line results expected late 2026 or early 2027, with a potential commercial launch in 2028.
• Management anticipates a strong finish to 2026 and continued growth into 2027, with no formal 2027 guidance provided yet.

Business Segments and Product Lines:

• BrionV (IV): 14th consecutive quarter of sequential growth; new patient starts accelerating in H2; 40% of new starts are treatment-naive (up from 25% at launch).
• Lifecycle Innovation (Enhanced): Phase 3b study met primary endpoint for bioequivalence of a single-dose initiation regimen (combining Day 1 and Day 15 doses); aims to simplify administration and reduce infusion-related reactions (16% vs. 26% standard).
• Subcutaneous BrionV: Phase 1 data shows 62% bioavailability and PK exposure exceeding IV bioequivalence; designed for quarterly self-administration via auto-injector.
• Azercel (CAR-T): First clinical results for allogeneic CD19 CAR-T in progressive MS show 90% of patients had stable/improved EDSS scores at day 90 with no grade 3+ CRS/ICANS or GVHD.
• New Indications: Phase 2 studies advancing in Generalized Myasthenia Gravis (sequence FCRN inhibition + BrionV) and Treatment-Resistant Schizophrenia (B-cell depletion).
• Hospital Segment: September and October marked the strongest hospital months since launch; adoption increasing among younger women (18–40).

Market and Competitive Landscape:

• BrionV strengthening competitive position against anti-CD20 peers (Ocrelizumab, Ofatumumab) with real-world data showing 99% relapse-free rate.
• Five-year comparative analysis suggests BrionV has a 44% lower risk of disability progression vs. Ocrelizumab and 49% vs. Ofatumumab.
• BTK inhibitors viewed as competitors primarily in the oral/genericized segment; efficacy and safety concerns (twice-daily dosing) limit their threat to high-efficacy CD20s.
• Targeting the 35% of new anti-CD20 starts currently choosing "stealth" (subcutaneous) administration, which represents a multi-billion dollar untapped opportunity.
• Competitive contracting acknowledged but deemed sustainable; gross-to-net ratio averaging 65% this year.

Risks and Challenges:

• Gross-to-Net Pressures: Potential future pressure from payer mix, government discounts, and contracting, though management offsets this via price increases.
• Regulatory Timelines: Success of Simplified IV initiation and Subcutaneous launch dependent on FDA approval (targeting mid-2027 and 2028, respectively).
• Competitive Dynamics: Evolution of competitor strategies (e.g., transition to subcutaneous) and the ongoing development of BTK inhibitors.
• Pipeline Uncertainty: Early-stage data for progressive MS CAR-T and new indications (MSH, Schizophrenia) require further maturation.
• 340B Policy: Potential exposure to pricing policy changes, though estimated impact is minimal (approx. 5% of business) as most patients are commercial.

Management Commentary and Tone:

• Tone is highly confident and positive, emphasizing "disciplined execution" and "meaningful progress."
• Management views the $1 billion revenue milestone as a starting line rather than a ceiling.
• CEO Michael Weiss highlighted that clinical evidence combined with patient experience drives adoption, reinforcing their market position.
• CFO Sean Power emphasized disciplined capital allocation, balancing R&D investment with shareholder returns (stock buybacks).
• Management believes BrionV has the potential to become the most prescribed anti-CD20 therapy for new MS treatment starts.

Analyst Questions and Answers:

• Gross-to-Net & Competition: CEO/CCO confirmed contracting is competitive and sustainable; pricing increases used to maintain net price stability. BTK inhibitors not seen as high-efficacy competitors to CD20s.
• 2027 Growth & Simplified IV: Growth expected to continue driven by new patient inflows and persistence; simplified IV regimen launch expected to provide tailwinds in H2 2027 with no immediate price impact (pricing remains same, just combined doses).
• Subcutaneous Launch Details: SubQ will launch with an auto-injector (not on-body injector); CMC readiness confirmed for 2028 launch. Community feedback favors the auto-injector pen-like device over on-body injectors.
• Hospital Momentum: Growth driven by expanding clinical evidence, physician confidence, DTC awareness, and institutional process improvements.
• New Patient vs. Switching: New patient growth is outpacing attrition; switching from other CD20s remains stable at ~33% of new starts.
• SubQ Uptake: Management anticipates faster uptake for SubQ than IV due to established brand, awareness, and existing commercial infrastructure.

Other Key Points:

• ECTRIMS data presentations included 7-year follow-up on BrionV (0.018 annualized relapse rate, 88% free of disability progression) and real-world data from ENABLE (>1,000 patients).
• SubQ dosing regimen of 400mg quarterly demonstrated robust B-cell depletion within four days.
• BrionV is being pursued in multiple indications simultaneously: Relapsing MS (IV/SubQ), Myasthenia Gravis, Schizophrenia, and Progressive MS (via Azercel).
• Patent portfolio extends into the mid-2040s, providing long-term runway for both IV and SubQ formulations.
• Management reiterated commitment to building a "value creation engine" beyond the initial MS franchise.